Transforming growth factor-β signaling through the Smad proteins: Role in systemic sclerosis

Autoimmunity Reviews

Volumn 5, Issue 8, 2006, Pages 563-569

  Verrecchia, Franck ^a   Mauviel, Alain ^a   Farge, Dominique ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Collagen genes; Fibrosis; Smad; Systemic sclerosis; Transforming growth factor

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; HALOFUGINONE; IMATINIB; INTERSTITIAL COLLAGENASE; PIRFENIDONE; SMAD PROTEIN; SMAD3 PROTEIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; CONNECTIVE TISSUE; DISEASE COURSE; DNA BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; GENE ACTIVATION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; KIDNEY; LUNG FIBROSIS; MORTALITY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION;

GENE EXPRESSION REGULATION; HUMANS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33749338087     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.06.001     Document Type: Review

References (39)

1. Feng X.H., and Derynck R. Specificity and versatility in TGF-signaling through Smads. Annu Rev Cell Dev Biol (2005)
2. Verrecchia F., and Mauviel A. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 4 (2002) 143-149
3. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
4. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29 (2004) 265-273
5. Trojanowska M., LeRoy E.C., Eckes B., and Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med 76 (1998) 266-274
6. Uitto J., and Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 24 Suppl 1 (2000) S60-S69
7. Verrecchia F., and Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118 (2002) 211-215
8. Verrecchia F., and Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 16 (2004) 873-880
9. Ghosh A.K. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 227 (2002) 301-314
10. Chung K.Y., Agarwal A., Uitto J., and Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 271 (1996) 3272-3278
11. Verrecchia F., Tacheau C., Wagner E.F., and Mauviel A. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J Biol Chem 278 (2003) 1585-1593
12. Verrecchia F., Wagner E.F., and Mauviel A. Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha. EMBO Rep 3 (2002) 1069-1074
13. Chen S.J., Yuan W., Mori Y., Levenson A., Trojanowska M., and Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 112 (1999) 49-57
14. Poncelet A.C., and Schnaper H.W. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem 276 (2001) 6983-6992
15. Verrecchia F., Chu M.L., and Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276 (2001) 17058-17062
16. Yuan W., and Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 276 (2001) 38502-38510
17. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85 (2004) 47-64
18. Leask A., and Abraham D.J. TGF-beta signaling and the fibrotic response. Faseb J 18 (2004) 816-827
19. Chin G.S., Liu W., Peled Z., Lee T.Y., Steinbrech D.S., Hsu M., et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 108 (2001) 423-429
20. Schmid P., Itin P., Cherry G., Bi C., and Cox D.A. Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 152 (1998) 485-493
21. Bonniaud P., Margetts P.J., Kolb M., Schroeder J.A., Kapoun A.M., Damm D., et al. Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171 (2005) 889-898
22. Flanders K.C., and Burmester J.K. Medical applications of transforming growth factor-beta. Clin Med Res 1 (2003) 13-20
23. Flanders K.C., Sullivan C.D., Fujii M., Sowers A., Anzano M.A., Arabshahi A., et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 160 (2002) 1057-1068
24. Zhao J., Shi W., Wang Y.L., Chen H., Bringas Jr. P., Datto M.B., et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 282 (2002) L585-L593
25. Nakao A., Fujii M., Matsumura R., Kumano K., Saito Y., Miyazono K., et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 104 (1999) 5-11
26. Abraham D.J., and Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26 (2005) 587-595
27. Derk C.T., and Jimenez S.A. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2 (2003) 181-191
28. Sakkas L.I. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 38 (2005) 113-116
29. Farge D., Henegar C., Carmagnat M., Daneshpouy M., Marjanovic Z., Rabian C., et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 52 (2005) 1555-1563
30. Furst D.E., and Clements P.J. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol Suppl 48 (1997) 53-57
31. Denton C.P., and Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13 (2001) 505-511
32. Mori Y., Chen S.J., and Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48 (2003) 1964-1978
33. Dong C., Zhu S., Wang T., Yoon W., Li Z., Alvarez R.J., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99 (2002) 3908-3913
34. Denton C.P., and Black C.M. Targeted therapy comes of age in scleroderma. Trends Immunol 26 (2005) 596-602
35. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
36. McSweeney P.A., Nash R.A., Sullivan K.M., Storek J., Crofford L.J., Dansey R., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100 (2002) 1602-1610
37. Farge D., Marolleau J.P., Zohar S., Marjanovic Z., Cabane J., Mounier N., et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 119 (2002) 726-739
38. Farge D., Passweg J., van Laar J.M., Marjanovic Z., Besenthal C., Finke J., et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis 63 (2004) 974-981
39. van Laar J.M., Farge D., and Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 64 (2005) 1515